Physician profile
Philip J Rosenfeld
NPI 1285659722
$205,873.12
in general payments reported to CMS, 2019-2025
17 companies · $27K in 2025
The $27K reported for 2025 was more than what 95% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $35K · 2021: $29K · 2022: $19K · 2023: $35K · 2024: $9,123 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $65K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,629 · Food and Beverage: $1,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $65,275.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,629.00 |
| Food and Beverage | $1,401.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $148,220.57 | 2019-2025 | Cirrus Hd-Oct, Plex Elite, Clarus |
| Apellis Pharmaceuticals, INC. | $18,424.90 | 2022-2025 | Syfovre |
| Regeneron Pharmaceuticals, INC. | $10,453.27 | 2020-2025 | Eylea, Eylea Hd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,342.00 | 2020-2023 | |
| F. Hoffmann-La Roche Ag | $5,819.00 | 2019-2024 | |
| Eyepoint US, INC. | $4,639.83 | 2020-2024 | |
| Biogen, INC. | $2,975.00 | 2020 | |
| Boehringer Ingelheim International Gmbh | $2,550.00 | 2022-2024 | |
| Abbvie INC. | $1,600.00 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $471.05 | 2025 | |
| Genentech, INC. | $145.92 | 2023 | Vabysmo, Susvimo, Lucentis |
| Johnson & Johnson Surgical Vision, INC. | $115.56 | 2024 | Tecnis Iol |
| Genentech USA, INC. | $89.39 | 2022-2023 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $26.63 | 2025 | Eylea Hd, Eylea |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Rosenfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.